Table 2 Demographic and clinical features of the hypertensive subjects, according to their ENaC variant status
| Â | Carriers of the ENaC variants | Non-carriers | |||
|---|---|---|---|---|---|
|  | βENaC i12-17CT (n = 16) | βENaC G589S (n = 8) | γENaC V546I (n = 8) | All (n = 32) | (n = 315) |
Female/male (n) | 9/7 | 4/4 | 7/1 | 20/12 | 166/149 |
Age (y) | 49.4 ± 8.5 | 49.3 ± 5.8 | 50.5 ± 9.0 | 49.7 ± 7.8 | 49.3 ± 10.2 |
BMI (kg/m2) | 28.0 ± 4.9 | 28.2 ± 4.8 | 27.9 ± 3.8 | 28.0 ± 4.5 | 27.4 ± 4.9 |
Serum creatinine (μmol/L) | 88 ± 18.9 | 91 ± 12.8 | 85 ± 17.1 | 88 ± 6.7 | 88 ± 15.1 |
Serum uric acid (μmol/L) | 329 ± 95.3 | 335 ± 65.6 | 386 ± 173.2 | 338 ± 87.1 | 340 ± 91.2 |
Fasting blood glucose (mmol/L) | 5.3 ± 0.9 | 5.7 ± 1.1 | 5.5 ± 0.9 | 5.4 ± 0.9 | 5.6 ± 1.1 |
Serum cholesterol (mmol/L) | 5.5 ± 0.8 | 6.0 ± 1.2 | 5.3 ± 0.7 | 5.6 ± 0.9 | 5.6 ± 1.0 |
Serum potassium (mmol/L) | 4.1 ± 0.3 | 4.2 ± 0.4 | 4.2 ± 0.5 | 4.2 ± 0.4 | 4.1 ± 0.3 |
Serum sodium (mmol/L) | 141 ± 2.4 | 140 ± 3.5 | 138 ± 2.2 | 140 ± 2.8 | 140 ± 0.3 |
Potassium supplementation (n) | 1 | 0 | 2 | 3 (9.4%) | 31 (9.8%) |
Cerebrovascular disorder (n) | 1 | 0 | 0 | 1 (3.1%) | 17 (5.4%) |
Diabetes (n) | 1 | 1 | 1 | 3 (9.4%) | 36 (11.4%) |
Gestational hypertension (n) | 3 | 1 | 2 | 6 (18.8%) | 44 (14.0%) |